CoChat
Sign Up
PreprintCited by 0Enzyme Structure and FunctionNeuroscience and Neuropharmacology ResearchAdvanced Electron Microscopy Techniques and Applications

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Structural mechanisms for VMAT2 inhibition by tetrabenazine

Open access
Dalton, Michael P., Cheng, Mary Hongying, Bahar, Ivet, Coleman, Jonathan A.·2024·eLife
DOI 10.7554/elife.91973.3

Preprint — published as 10.7554/elife.91973.4 · Paper page

Open this paper in CoChat — free account

Abstract

Abstract The vesicular monoamine transporter 2 (VMAT2) is a proton-dependent antiporter responsible for loading monoamine neurotransmitters into synaptic vesicles. Dysregulation of VMAT2 can lead to several neuropsychiatric disorders including Parkinson’s disease and schizophrenia. Furthermore, drugs such as amphetamine and MDMA are known to act on VMAT2, exemplifying its role in the mechanisms of actions for drugs of abuse. Despite VMAT2’s importance, there remains a critical lack of mechanistic understanding, largely driven by a lack of structural information. Here we report a 3.1 Å resolution cryo-EM structure of VMAT2 complexed with tetrabenazine (TBZ), a non-competitive inhibitor used in the treatment of Huntington’s chorea. We find TBZ interacts with residues in a central binding site, locking VMAT2 in an occluded conformation and providing a mechanistic basis for non-competitive inhibition. We further identify residues critical for cytosolic and lumenal gating, including a cluster of hydrophobic residues which are involved in a lumenal gating strategy. Our structure also highlights three distinct polar networks that may determine VMAT2 conformational dynamics and play a role in proton transduction. The structure elucidates mechanisms of VMAT2 inhibition and transport, providing insights into VMAT2 architecture, function, and the design of small-molecule therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.91973.3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 97

  1. 1957, 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists, Nature, 180, 1200, 10.1038/1801200a0 · DOI
  2. 1962, Uptake of catecholamines by a particulate fraction of the adrenal medulla, J Biol Chem, 237, 2311, 10.1016/S0021-9258(19)63439-3 · DOI
  3. 2011, VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse, Ann N Acad Sci, 1216, 86, 10.1111/j.1749-6632.2010.05906.x · DOI
  4. 1998, The vesicular monoamine transporter: from chromaffin granule to brain, Neurochem Int, 32, 227, 10.1016/S0197-0186(97)00092-2 · DOI
  5. 2000, The vesicular neurotransmitter transporters: current perspectives and future prospects, FASEB J, 14, 2396, 10.1096/fj.00-0817rev · DOI
  6. 1988, Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport, Physiol Rev, 68, 232, 10.1152/physrev.1988.68.1.232 · DOI
  7. 2004, The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine, Pflugers Arch, 447, 636, 10.1007/s00424-003-1100-5 · DOI
  8. 1995, Vesicular neurotransmitter transporters: from bacteria to humans, Physiol Rev, 75, 369, 10.1152/physrev.1995.75.2.369 · DOI
  9. 1994, The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors, J Biol Chem, 269, 7231, 10.1016/S0021-9258(17)37272-1 · DOI
  10. 2016, Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain, Nat Commun, 7
  11. 1992, A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter, Cell, 70, 539, 10.1016/0092-8674(92)90425-C · DOI
  12. 1995, Differential expression of two vesicular monoamine transporters, J Neurosci, 15, 6179, 10.1523/JNEUROSCI.15-09-06179.1995 · DOI
  13. 1992, Expression cloning of a reserpine-sensitive vesicular monoamine transporter, Proc Natl Acad Sci U A, 89, 10993, 10.1073/pnas.89.22.10993 · DOI
  14. 1994, Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat, J Mol Neurosci, 5, 149, 10.1007/BF02736730 · DOI
  15. 1997, Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine, Neuron, 19, 1285, 10.1016/S0896-6273(00)80419-5 · DOI
  16. 1997, VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity, Proc Natl Acad Sci U A, 94, 9938, 10.1073/pnas.94.18.9938 · DOI
  17. 1997, Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action, Neuron, 19, 1271, 10.1016/S0896-6273(00)80418-3 · DOI
  18. 2006, Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder, Neuropsychopharmacology, 31, 2739, 10.1038/sj.npp.1301196 · DOI
  19. 2016, A Functional Vesicular Monoamine Transporter 1 (VMAT1) Gene Variant Is Associated with Affect and the Prevalence of Anxiety, Affective, and Alcohol Use Disorders in a Longitudinal Population-Representative Birth Cohort Study, Int J Neuropsychopharmacol, 19
  20. 2013, Association of VMAT2 gene polymorphisms with alcohol dependence, J Neural Transm Vienna, 120, 1161, 10.1007/s00702-013-0996-y · DOI
  21. 2006, Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease, J Cereb Blood Flow Metab, 26, 1198, 10.1038/sj.jcbfm.9600276 · DOI
  22. 2020, The Gene Polymorphism of VMAT2 Is Associated with Risk of Schizophrenia in Male Han Chinese, Psychiatry Investig, 17, 1073, 10.30773/pi.2020.0023 · DOI
  23. 2013, Group. Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition, Schizophr Bull, 39, 848, 10.1093/schbul/sbs067 · DOI
  24. 2008, Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia, Neuropsychobiology, 57, 55, 10.1159/000129668 · DOI
  25. 1997, Vesicular acetylcholine transporter (VAChT) protein: a novel and unique marker for cholinergic neurons in the central and peripheral nervous systems, J Comp Neurol, 378, 454, 10.1002/(SICI)1096-9861(19970224)378:4<454::AID-CNE2>3.0.CO;2-1 · DOI
  26. 2014, Identification of a mammalian vesicular polyamine transporter, Sci Rep, 4, 6836, 10.1038/srep06836 · DOI
  27. 1966, Simple allosteric model for membrane pumps, Nature, 211, 969, 10.1038/211969a0 · DOI
  28. 1957, A general theory of membrane transport from studies of bacteria, Nature, 180, 134, 10.1038/180134a0 · DOI
  29. 2011, The alternating-access mechanism of MFS transporters arises from inverted-topology repeats, J Mol Biol, 407, 698, 10.1016/j.jmb.2011.02.008 · DOI
  30. 2018, The ins and outs of vesicular monoamine transporters, J Gen Physiol, 150, 671, 10.1085/jgp.201711980 · DOI
  31. 2013, Identification of molecular hinge points mediating alternating access in the vesicular monoamine transporter VMAT2, Proc Natl Acad Sci U A, 110, E1332
  32. 2016, Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis, Proc Natl Acad Sci U A, 113, E7390
  33. 1996, Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter, Proc Natl Acad Sci U A, 93, 5166, 10.1073/pnas.93.10.5166 · DOI
  34. 2016, Tetrabenazine: Spotlight on Drug Review, Ann Neurosci, 23, 176, 10.1159/000449184 · DOI
  35. 1983, Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine, Proc Natl Acad Sci U A, 80, 584, 10.1073/pnas.80.2.584 · DOI
  36. 1984, Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding, Mol Pharmacol, 25, 113, 10.1016/S0026-895X(25)15021-9 · DOI
  37. 2013, Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine, J Biol Chem, 288, 32160, 10.1074/jbc.M113.502971 · DOI
  38. 2010, Structural and thermodynamic analysis of the GFP:GFP-nanobody complex, Protein Sci, 19, 2389, 10.1002/pro.519 · DOI
  39. 2018, The ins and outs of vesicular monoamine transporters, J Gen Physiol, 150, 671, 10.1085/jgp.201711980 · DOI
  40. 2007, The vesicular monoamine transporter 2 contains trafficking signals in both its N-glycosylation and C-terminal domains, J Neurochem, 100, 1387, 10.1111/j.1471-4159.2006.04326.x · DOI
  41. 2002, Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond, Biochemistry, 41, 6346, 10.1021/bi015779j · DOI
  42. 1997, Charged Residues in Transmembrane Domains II and XI of a Vesicular Monoamine Transporter Form a Charge Pair That Promotes High Affinity Substrate Recognition, J. Biol. Chem, 272, 5403, 10.1074/jbc.272.9.5403 · DOI
  43. 2005, Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters, Nature, 437, 215, 10.1038/nature03978 · DOI
  44. 2022, Inhibition of VMAT2 by beta2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone, Commun Biol, 5, 1283, 10.1038/s42003-022-04121-1 · DOI
  45. 2001, Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport, J Biol Chem, 276, 27304, 10.1074/jbc.M103947200 · DOI
  46. 2021, Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS), Chem Rev, 121, 5289, 10.1021/acs.chemrev.0c00983 · DOI
  47. 2012, Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature, Clin Ther, 34, 1487, 10.1016/j.clinthera.2012.06.010 · DOI
  48. 2020, Ion transport and regulation in a synaptic vesicle glutamate transporter, Science, 368, 893, 10.1126/science.aba9202 · DOI
  49. 2022, Cryo-EM structure of human glucose transporter GLUT4, Nat Commun, 13, 2671, 10.1038/s41467-022-30235-5 · DOI
  50. 2020, Synthetic antibodies against BRIL as universal fiducial marks for single−particle cryoEM structure determination of membrane proteins, Nat. Commun, 11, 1598, 10.1038/s41467-020-15363-0 · DOI
  51. 2023, Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate, Cell, 186, 2644, 10.1016/j.cell.2023.04.028 · DOI
  52. 2012, A fluorescence-detection size-exclusion chromatography-based thermostability assay for membrane protein precrystallization screening, Structure, 20, 1293, 10.1016/j.str.2012.06.009 · DOI
  53. 2016, Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder, J. Inherit. Metab. Dis, 39, 305, 10.1007/s10545-015-9897-6 · DOI
  54. 2013, Brain Dopamine–Serotonin Vesicular Transport Disease and Its Treatment, N. Engl. J. Med, 368, 543, 10.1056/NEJMoa1207281 · DOI
  55. 2019, A novel missense variant in SLC18A2 causes recessive brain monoamine vesicular transport disease and absent serotonin in platelets, JIMD Rep, 47, 9
  56. 2023, Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individuals, Genet. Med, 25, 90, 10.1016/j.gim.2022.09.010 · DOI
  57. 2011, Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors, Eur J Med Chem, 46, 1841, 10.1016/j.ejmech.2011.02.046 · DOI
  58. 2018, Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia, P T Peer-Rev. J. Formul. Manag, 43, 328
  59. 2006, Cyan and Yellow Super Fluorescent Proteins with Improved Brightness, Protein Folding, and FRET Förster Radius, Biochemistry, 45, 6570, 10.1021/bi0516273 · DOI
  60. 2008, A Versatile Nanotrap for Biochemical and Functional Studies with Fluorescent Fusion Proteins, Mol. Cell. Proteomics, 7, 282, 10.1074/mcp.M700342-MCP200 · DOI
  61. 2002, Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line, Proc. Natl. Acad. Sci, 99, 13419, 10.1073/pnas.212519299 · DOI
  62. 2014, Screening and large-scale expression of membrane proteins in mammalian cells for structural studies, Nat Protoc, 9, 2574, 10.1038/nprot.2014.173 · DOI
  63. 2003, SerialEM: A Program for Automated Tilt Series Acquisition on Tecnai Microscopes Using Prediction of Specimen Position, Microsc. Microanal, 9, 1182, 10.1017/S1431927603445911 · DOI
  64. 2017, cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination, Nat Methods, 14, 290, 10.1038/nmeth.4169 · DOI · Paper page
  65. 2020, Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction, Nat Methods, 17, 1214, 10.1038/s41592-020-00990-8 · DOI
  66. 2012, RELION: implementation of a Bayesian approach to cryo-EM structure determination, J Struct Biol, 180, 519, 10.1016/j.jsb.2012.09.006 · DOI · Paper page
  67. 2021, DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun, Biol, 4
  68. 2016, Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta, Elife, 5
  69. 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr Biol Crystallogr, 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
  70. 2018, ISOLDE□: a physically realistic environment for model building into low-resolution electron-density maps, Acta Crystallogr. Sect. Struct. Biol, 74, 519, 10.1107/S2059798318002425 · DOI
  71. 2019, Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix, Acta Crystallogr Struct Biol, 75, 861, 10.1107/S2059798319011471 · DOI · Paper page
  72. 2015, Thermostabilization of the Human Serotonin Transporter in an Antidepressant-Bound Conformation, PLoS One, 10, e0145688, 10.1371/journal.pone.0145688 · DOI
  73. 2014, CHARMM-GUI Membrane Builder toward realistic biological membrane simulations, J. Comput. Chem, 35, 1997, 10.1002/jcc.23702 · DOI
  74. 2012, OPM database and PPM web server: resources for positioning of proteins in membranes, Nucleic Acids Res, 40, D370, 10.1093/nar/gkr703 · DOI
  75. 2011, PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical p K a Predictions, J. Chem. Theory Comput, 7, 525, 10.1021/ct100578z · DOI
  76. 2005, Scalable molecular dynamics with NAMD, J. Comput. Chem, 26, 1781, 10.1002/jcc.20289 · DOI · Paper page
  77. 2016, CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field, J. Chem. Theory Comput, 12, 405, 10.1021/acs.jctc.5b00935 · DOI
  78. 2010, Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types, J. Phys. Chem. B, 114, 7830, 10.1021/jp101759q · DOI
  79. 2017, CHARMM36m: an improved force field for folded and intrinsically disordered proteins, Nat. Methods, 14, 71, 10.1038/nmeth.4067 · DOI
  80. 2012, Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges, J. Chem. Inf. Model, 52, 3155, 10.1021/ci3003649 · DOI
  81. 2011, Open Babel: An open chemical toolbox, J. Cheminformatics, 3, 33, 10.1186/1758-2946-3-33 · DOI
  82. 1985, Canonical dynamics: Equilibrium phase-space distributions, Phys. Rev. A, 31, 1695, 10.1103/PhysRevA.31.1695 · DOI
  83. 1984, A molecular dynamics method for simulations in the canonical ensemble, Mol. Phys, 52, 255, 10.1080/00268978400101201 · DOI
  84. 1995, A smooth particle mesh Ewald method, J. Chem. Phys, 103, 8577, 10.1063/1.470117 · DOI
  85. 1977, Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes, J. Comput. Phys, 23, 327, 10.1016/0021-9991(77)90098-5 · DOI
  86. 2018, Quantitative Assessment of the Energetics of Dopamine Translocation by Human Dopamine Transporter, J. Phys. Chem. B, 122, 5336, 10.1021/acs.jpcb.7b10340 · DOI
  87. 2005, Exploring the free-energy landscape of a short peptide using an average force, J. Chem. Phys, 123
  88. 2009, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J. Comput. Chem. NA-NA, 10.1002/jcc.21334 · DOI · Paper page
  89. 2015, Insights into the Modulation of Dopamine Transporter Function by Amphetamine, Orphenadrine, and Cocaine Binding, Front. Neurol, 6
  90. 2021, Illumination of serotonin transporter mechanism and role of the allosteric site, Sci Adv, 7, eabl3857, 10.1126/sciadv.abl3857 · DOI
  91. 1996, VMD: Visual molecular dynamics, J. Mol. Graph, 14, 33, 10.1016/0263-7855(96)00018-5 · DOI · Paper page
  92. 2019, Large-scale prediction of binding affinity in protein–small ligand complexes: the PRODIGY-LIG web server, Bioinformatics, 35, 1585, 10.1093/bioinformatics/bty816 · DOI
  93. 2020, Essential site scanning analysis: A new approach for detecting sites that modulate the dispersion of protein global motions, Comput. Struct. Biotechnol. J, 18, 1577, 10.1016/j.csbj.2020.06.020 · DOI
  94. 2009, Fpocket: An open source platform for ligand pocket detection, BMC Bioinformatics, 10
  95. 2021, ProDy 2.0: increased scale and scope after 10 years of protein dynamics modelling with Python, Bioinformatics, 37, 3657, 10.1093/bioinformatics/btab187 · DOI
  96. 2023, Using evolutionary data to make sense of macromolecules with a “face-lifted” ConSurf, Protein Sci, 32
  97. 2008, PROMALS3D: a tool for multiple protein sequence and structure alignments, Nucleic Acids Res, 36, 2295, 10.1093/nar/gkn072 · DOI

Metadata

Authors
Dalton, M. P., Cheng, M. H., Bahar, I., & Coleman, J. A.
Affiliations
  • University of Pittsburgh (US)
  • Laufer Center for Physical and Quantitative Biology, and Department of Biochemistry and Cell Biology, School of Medicine, Stony Brook University
Corresponding author
Coleman, Jonathan A.
ORCID
Venue
eLife
Publisher
eLife Sciences Publications, Ltd
Published
2024-03-04
ISSN
2050-084X (ISSN-L)
DOI
10.7554/elife.91973.3
OpenAlex
W4392367212
Cited by
0
References
1
Type
posted content
Language
en
Open access
Licence
Locations
eLife (acceptedVersion, cc-by)
Funders
  • National Institute of Neurological Disorders and Stroke (1R01NS134558)
  • National Institute of General Medical Sciences (1R01GM139297)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Advanced Electron Microscopy Techniques and Applications
Keywords
vesicular monoamine transporter 2, tetrabenazine, vesicular monoamine transporter, non-competitive inhibition, cryo-EM structure, monoamine transport, synaptic vesicles, conformational dynamics, Huntington's disease, Parkinson's disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review